DNAtriX

DNAtrix is a Texas-based company developing modified viruses for the treatment of the most aggressive forms of cancer. The company’s initial focus is on glioblastoma, a devastating brain tumor that is currently incurable. Since viruses are already good at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. More than 35 patients have been treated with the cancer-killing virus, called DNX-2401, with excellent early results. Company’s lead product, DNX-2401, is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, including brain metastases, ovarian and pancreatic cancer. Targeted cancer-killing viruses such as DNX-2401 represent an important new weapon in the fight against cancer.

DNAtriX headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $8.9B in funding across 156 round(s). With a team of 1-10 employees, DNAtriX is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - DNAtriX, raised $885.6K. Discover more about their projects, partnerships, and impact on our platform.